Newer anaesthetic agents, such as remifentanil and sevoflurane, are more expensive than conventional anaesthetics, such as isoflurane and fentanyl. However, newer anaesthetics might outweigh their higher acquisition costs by reducing length of stay in the postanaesthesia care unit and thereby reducing personnel costs. We retrospectively investigated the influence of newer anaesthetics on time to eligibility for discharge from the postanaesthesia care unit in consecutive patients undergoing major abdominal surgery.
Health care institutions have to face economic pressures. The largest single cost category of total hospital costs for surgical patients is the perioperative period. Costs associated with care in the postanaesthesia care unit (PACU) contribute a substantial portion of the operating room costs 1 . Whereas medical supplies and drugs account for only 2% of PACU charges, personnel costs account for almost all of the remaining 98%. Effective savings are possible by decreasing the necessity and length of stay for postanaesthesia patients in PACU 2 . Fast-track anaesthesia, allowing early extubation and accelerated patient transfer to normal ward or discharge home, has become widely used for a number of surgical procedures. Newer anaesthetics such as remifentanil and sevoflurane, characterized by a faster onset and offset, may allow good intraoperative titration, prompt postoperative extubation, and fast recovery after general anaesthesia. On the other hand, newer anaesthetics are more expensive than conventional anaesthetics [3] [4] [5] . However, taking the possible reduced length of stay in PACU into account, these more cost inten-sive anaesthetics might reduce the overall costs by reducing length of stay in PACU 6, 7 . In patients undergoing gynaecological surgery, extubation times were reduced by newer anaesthetics, but the cost-relevant length of stay in PACU and total hospital costs were unchanged 8 . Another study reported an improvement of the throughput of patients in PACU by using newer anaesthetic agents in patients undergoing abdominal surgery. Therefore, it is controversial whether newer anaesthetics are cost effective 4, 6, 9, 10 .
Furthermore, studies investigating the effects of newer anaesthetics on recovery primarily included ambulatory anaesthesia for minor surgery in otherwise healthy patients 9, [11] [12] [13] . Only one study investigated the influence of newer anaesthetics on length of stay in PACU in major abdominal surgery, and found no difference of alfentanil versus remifentanil concerning length of stay in PACU 14 . Accordingly, we investigated the influence of newer anaesthetics on length of stay in PACU in patients undergoing major abdominal surgery.
MATERIAL AND METHODS
After institutional approval, data of consecutive patients undergoing major abdominal surgery in a sixmonth period at the University Hospital of Vienna were retrospectively analysed by chart review. Inclusion criteria were physical status II-IV according the American Society of Anesthesiologists (ASA), major abdominal surgery, patient age 18 years or older, extubation in the operating room and postoperative recovery in the PACU. Exclusion criteria were supplemental regional anaesthesia and revision or emergency surgery. Anaesthesia was delivered by residents and supervised by consultants of our anaesthesia department. Three anaesthetic regimens were compared: isoflurane/fentanyl (ISO/FENTA), sevoflurane/fentanyl (SEVO/FENTA), and sevoflurane/ remifentanil (SEVO/REMI).
Propofol served as induction agent (1.5 to 2.5 mg.kg -1 ) in all patients. In the ISO/FENTA and SEVO/FENTA group a bolus of 1.5 µg.kg -1 fentanyl was given for induction followed by repeated bolus doses as appropriate. In the SEVO/REMI group a bolus dose of 0.5 to 1 µg.kg -1 remifentanil was given over 30-60 seconds followed by a continuous infusion of remifentanil (0.15-0.5 µg.kg -1 .min -1 ) as appropriate. Vecuronium or cisatracurium was administered to facilitate orotracheal intubation. After orotracheal intubation, patients' lungs were ventilated mechanically with a 1:2 oxygen-air mixture. Anaesthesia was maintained either by using isoflurane or sevoflurane as inhalational anaesthetics (MAC 1.0 to 1.5). Fluid and blood substitution was administered as appropriate. Forced-air warming and warmed infusions were used to prevent hypothermia. Analgesics and anaesthetics were adjusted and at the end of surgery, discontinued by the responsible anaesthesiologist as appropriate. At the end of surgery muscle relaxants were antagonized if they were given within the previous 30 minutes, and depending on the muscle strength, using intravenous (IV) neostigmine 50 µg.kg -1 . Glycopyrrolate was administered with neostigmine 15 . Naloxone was not used. Patients were extubated in the operating room as soon as they breathed satisfactorily alone and opened their eyes on command. Afterwards patients were transferred to PACU with the possibility for advanced monitoring and tools for active patient warming and temperature measurement. Postanaesthesia recovery was scored according to the Aldrete scoring system, which includes patient activity, blood pressure, consciousness and skin colouration. Eligibility for PACU discharge was decided by registered nurses on the basis of the Aldrete Score. Criteria for discharge from PACU were defined as Aldrete Score >8 with pain, shivering, nausea and vomiting controlled 16 . Postoperative pain was treated by diclofenac (75 mg IV as short infusion) and by IV administration of piritramide. For treatment of postoperative nausea and vomiting (PONV) 10 mg metoclopramide and/or 4 to 8 mg ondansetron were given.
Relevant time points were defined and measured as follows: duration of anaesthesia, i.e. from start of monitoring till extubation; duration of surgical intervention (from skin incision till last skin suture); time to extubation (from last skin suture to extubation); duration of stay in PACU (from admission till reaching discharge criteria to normal ward). Demographic data (age, sex, height, weight, and ASA classification), need for postoperative analgesics and the incidence of PONV were recorded. The study period ended when patients reached discharge criteria from PACU.
After testing for normal distribution of the data (Kolmogorov-Smirnov test), Kruskal-Wallis test was performed to test for differences between the different anaesthetic regimens. P values 0.05 were considered significant.
RESULTS
There were 258 consecutive patients undergoing major abdominal surgery over the study period. Ninety-six patients had to be excluded from analysis according to the inclusion/exclusion criteria described above: <18 years (n=6), unplanned postoperative transfer to intensive care unit (n=11), additional regional anaesthesia (n=12), use of other anaesthetics (continuous infusion of propofol and different opioid regimens) (n=42), ASA I (n=3), and revision or emergency surgery (n=22). Thus, 162 patients were eligible for analysis distributed as follows: ISO/ FENTA; n=80, SEVO/FENTA; n=40, and SEVO/ REMI; n=42.
The three groups did not differ with regard to gender, height, weight, surgical procedures, duration of anaesthesia, duration of surgery or ASA classification. The age of the SEVO/FENTA group was higher compared to both other groups. Fentanyl requirements in the ISO/FENTA and SEVO/FENTA group were comparable (0.66±0.35 mg vs 0.59± 0.35 mg; P=0.7).
Extubation times were shorter in the SEVO/ FENTA and SEVO/REMI group compared to the ISO/FENTA group. Length of Stay in PACU was similar in ISO/FENTA and SEVO/REMI, and showed a tendency to be increased in the SEVO/ FENTA group (P=0.08).
The incidence of PONV and the need for piritramide in PACU was higher in the SEVO/REMI group compared to both other groups. No patient had any early postoperative (anaesthesia related) complications, e.g. reintubation or organ failure.
DISCUSSION
In this study, the effects of newer anaesthetics on length of stay in PACU were determined in patients undergoing major abdominal surgery. Compared to previous studies, we investigated patients with higher ASA classifications, who underwent surgery of longer duration and were on average, older 9, 17 . We did not include ASA I patients because in our institution it is rare for these patients to require major abdominal surgery. Our data showed no benefit regarding time to eligibility to discharge from the PACU in patients undergoing general anaesthesia using sevoflurane and remifentanil compared to isoflurane and fentanyl.
This study had several limitations due to its retrospective nature, lack of randomization and blinding, and lack of fixed protocols. Nevertheless, there appeared to be no differences between the three groups in relation to ASA physical status, height, weight, or duration of anaesthesia or surgery. The mean age was greater in the SEVO/FENTA group, but there was no significant age difference between the ISO/FENTA group and the SEVO/REMI group. Moreover, although there were no strict protocols, perioperative management within each group was relatively standardized and not influenced by comorbidities. In any event, blinding would not have been possible for the remifentanil group due to the requirement for early introduction of alternative analgesia. We assessed time to eligibility for discharge from PACU rather than total PACU length of stay, because time to actual discharge from PACU may be influenced by other factors. Therefore, while not providing "proof", our results suggest that there is little benefit in terms of time to eligibility for discharge from PACU, for patients undergoing major abdominal surgery, at least in our institution.
This finding is of interest as it has been controver- sial whether the more expensive newer anaesthetics might reduce length of stay in PACU and thereby outweigh their higher acquisition costs, by reducing personnel costs 4, 6, 9, 10 . The failure of newer anaesthetics to reduce length of stay in PACU in our study could have been caused by two factors. Firstly, the SEVO/ REMI group showed higher postoperative need for analgesics compared to both fentanyl groups. This could have offset the faster recovery after anaesthesia with newer anaesthetics, which was documented by faster extubation times. Secondly, the higher incidence of postoperative nausea and vomiting in the SEVO/REMI group could have delayed discharge from PACU. It has been shown previously that postoperative nausea and vomiting prolongs length of stay in PACU 2 . There is some evidence that remifentanil increases postoperative nausea and vomiting compared to longer acting opioids 9, 18 . We can make no statement as to whether the increased incidence of postoperative nausea and vomiting in the SEVO/ REMI group was caused by remifentanil or by the increased use of piritramide in this group. However, the regimen SEVO/REMI without careful transition to longer-acting analgesics cannot be recommended as it appears to be associated with increased requirements for analgesia and increased postoperative nausea and vomiting in the PACU.
Time to eligibility to discharge from PACU tended to be slightly higher in the SEVO/FENTA group compared to the other groups. However, the patients in this group were significantly older than the other two groups, which might explain the differences. On the other hand, the ISO/FENTA and the SEVO/REMI groups showed no difference in demography and were therefore not influenced by age.
An interesting additional finding was that the extubation times were the same in the SEVO/FENTA and in the SEVO/REMI groups. Therefore, it is possible that the decrease of extubation times by newer anaesthetics was caused by sevoflurane rather than by remifentanil. However, prospective randomized trials would be required to confirm this observation.
The time to eligibility for discharge from PACU was relatively long in our study. This could have been caused by the long duration of surgery and anaesthesia, and by patient co-morbidites. Studies investigating the effects of newer anaesthetics have previously mainly covered the field of ambulatory anaesthesia for minor surgery in otherwise healthy patients 9, [11] [12] [13] . Only one study investigated the influence of newer anaesthetics on length of stay in PACU in major surgery. Schüttler et al compared the influence of alfentanil versus remifentanil in patients undergoing major abdominal surgery and found no difference in both groups concerning length of stay in PACU 14 . In their study duration of anaesthesia was approximately 170 minutes, and length of stay in PACU was approximately 200 minutes. Therefore, length of stay in PACU of approximately 265 minutes in our study seems to be reasonable, as duration of anaesthesia was approximately 235 minutes and ASA classifications were higher in our patients.
In conclusion, in our institution, sevoflurane and remifentanil did not appear to reduce time to eligibility to discharge from PACU in patients undergoing major abdominal surgery, compared to isoflurane and fentanyl. This suggests that factors other than anaesthesia technique are responsible for the time to eligibility for discharge from PACU in this group of patients. This study also highlights the necessity for carefully planned transition from remifentanil to other longer-acting analgesia. While this study is limited by its retrospective nature, the findings question the effect of these newer anaesthetic agents on time to eligibility to discharge from PACU in patients undergoing major surgery.
